Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.44 |
| ▸ | EBP | Q15125 | 3/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17778824 | 0.92 | SIGMAR1 (0.51) | HRH3OPRL1OPRM1OPRK1SIGMAR1 | |
| SCHEMBL17778818 | 0.88 | OPRL1 (0.57) | HRH3OPRL1OPRM1OPRK1SIGMAR1 | |
| SCHEMBL17778814 | 0.84 | HRH3 (0.55) | HRH3SIGMAR1NPY5R | |
| SCHEMBL13314935 | 0.81 | OPRL1 (0.53) | OPRL1OPRM1OPRK1SIGMAR1EBP | |
| SCHEMBL17778827 | 0.79 | SIGMAR1 (0.51) | OPRL1OPRM1SIGMAR1 | |
| SCHEMBL17779118 | 0.76 | HRH3 (0.68) | HRH3OPRK1SIGMAR1NPY5R | |
| SCHEMBL29931876 | 0.76 | SIGMAR1 (0.58) | HRH3SIGMAR1NPY5RDRD2 | |
| SCHEMBL1952165 | 0.76 | SIGMAR1 (0.58) | HRH3SIGMAR1NPY5RDRD2 | |
| SCHEMBL12935322 | 0.75 | HRH3 (0.44) | HRH3OPRL1OPRM1OPRK1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL20954780 | 0.75 | SIGMAR1 (0.57) | HRH3SIGMAR1NPY5RDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407428-B2 | Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-09-10 | — | — | US | disclosed |
| US-20180111935-A1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-04-26 | — | — | US | disclosed |
| US-20180111935-A1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-04-26 | — | — | US | disclosed |
| WO-2016078770-A1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407428-B2 | Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain | OPRD1, OPRK1, OPRL1 | HRH3 1418/4885OPRL1 3/4885OPRM1 4/4885 |
| US-20180111935-A1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRK1, OPRL1 | HRH3 1409/4885OPRL1 3/4885OPRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.